Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belinostat - Onxeo

Drug Profile

Belinostat - Onxeo

Alternative Names: Beleodaq; CLN-9; PDX 101; PX-105684; PXD 101

Latest Information Update: 14 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TopoTarget
  • Developer Acrotech Biopharma; CIMA- Universidad de Navarra; Emory University; National Cancer Institute (USA); Onxeo SA; Servier; TopoTarget
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Malignant thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase II B-cell lymphoma; Glioblastoma
  • Phase I/II Non-small cell lung cancer
  • Preclinical Liver cancer; Solid tumours
  • No development reported Acute myeloid leukaemia; Bladder cancer; Carcinoma; Colorectal cancer; Cutaneous T-cell lymphoma; Fallopian tube cancer; Lymphoma; Malignant thymoma; Mesothelioma; Myelodysplastic syndromes; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Soft tissue sarcoma
  • Discontinued Multiple myeloma

Most Recent Events

  • 10 Apr 2020 National Cancer Institute plans a phase II trial for Chondrosarcoma (Combination therapy, Late-stage disease, Uresectable/Inoperable, Metastatic disease, Second-line therapy or greater) (NCT04340843)
  • 07 Apr 2020 Acrotech Biopharma gains worldwide license to belinostat from Onxeo
  • 07 Dec 2019 Efficacy data from a phase II trial in T cell lymphoma presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top